Home > Publications database > Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. > print

001     131758
005     20240229105011.0
024 7 _ |a 10.1002/ijc.31058
|2 doi
024 7 _ |a pmid:28921520
|2 pmid
024 7 _ |a pmc:PMC5749630
|2 pmc
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:26312170
|2 altmetric
037 _ _ |a DKFZ-2018-00057
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Jung, Seungyoun
|0 0000-0002-9887-2389
|b 0
245 _ _ |a Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.
260 _ _ |a Bognor Regis
|c 2018
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521456589_14509
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Anti-Mullerian Hormone
|0 80497-65-0
|2 NLM Chemicals
700 1 _ |a Allen, Naomi
|b 1
700 1 _ |a Arslan, Alan A
|b 2
700 1 _ |a Baglietto, Laura
|b 3
700 1 _ |a Barricarte, Aurelio
|b 4
700 1 _ |a Brinton, Louise A
|0 0000-0003-3853-8562
|b 5
700 1 _ |a Egleston, Brian L
|b 6
700 1 _ |a Falk, Roni T
|b 7
700 1 _ |a Fortner, Renée T
|0 0000-0002-1426-8505
|b 8
700 1 _ |a Helzlsouer, Kathy J
|b 9
700 1 _ |a Gao, Yutang
|b 10
700 1 _ |a Idahl, Annika
|b 11
700 1 _ |a Kaaks, Rudolph
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Krogh, Vittorio
|0 0000-0003-0122-8624
|b 13
700 1 _ |a Merritt, Melissa A
|b 14
700 1 _ |a Lundin, Eva
|b 15
700 1 _ |a Onland-Moret, N Charlotte
|b 16
700 1 _ |a Rinaldi, Sabina
|b 17
700 1 _ |a Schock, Helena
|0 P:(DE-He78)1bd6298f721e4a01f21c2329276a53a7
|b 18
|u dkfz
700 1 _ |a Shu, Xiao-Ou
|b 19
700 1 _ |a Sluss, Patrick M
|b 20
700 1 _ |a Staats, Paul N
|b 21
700 1 _ |a Sacerdote, Carlotta
|0 0000-0002-8008-5096
|b 22
700 1 _ |a Travis, Ruth C
|b 23
700 1 _ |a Tjønneland, Anne
|b 24
700 1 _ |a Trichopoulou, Antonia
|b 25
700 1 _ |a Tworoger, Shelley S
|b 26
700 1 _ |a Visvanathan, Kala
|b 27
700 1 _ |a Weiderpass, Elisabete
|b 28
700 1 _ |a Zeleniuch-Jacquotte, Anne
|b 29
700 1 _ |a Dorgan, Joanne F
|b 30
773 _ _ |a 10.1002/ijc.31058
|g Vol. 142, no. 2, p. 262 - 270
|0 PERI:(DE-600)1474822-8
|n 2
|p 262 - 270
|t International journal of cancer
|v 142
|y 2018
|x 0020-7136
909 C O |o oai:inrepo02.dkfz.de:131758
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 0000-0002-1426-8505
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)1bd6298f721e4a01f21c2329276a53a7
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2015
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21